Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population

The 21‐gene signature has been intensively studied and incorporated into major guidelines for treatment decision in early breast caner. However, it remains to be examined whether this system is applicable to Asian populations.

[1]  田村 隆行.  Annual San Antonio Breast Cancer Symposium に参加して , 2011 .

[2]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[3]  J. Cuzick,et al.  Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. , 2009 .

[4]  W. Alexander,et al.  American Society of Clinical Oncology , 2020, Definitions.

[5]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Cronin,et al.  Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. , 2007, Clinical chemistry.

[7]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Shak,et al.  A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients , 2006, Breast Cancer Research.

[10]  M. Izuo,et al.  The general rules for clinical and pathological recording of breast cancer , 1989, The Japanese journal of surgery.

[11]  J. Misumi,et al.  The time trend of breast cancer mortality in Japan , 2005, Archives of Gynecology and Obstetrics.

[12]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[13]  Debjani Dutta,et al.  Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. , 2004, The American journal of pathology.